Caplin Point Laboratories Q1 Results FY26: Q1 PAT Rises 23.26% to ₹152.80 Crore; Revenue Up 11.17% YoY

Caplin Point Laboratories Q1 Results FY26: Caplin Point Laboratories posted its Q1 results on 6th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹152.80 crores against revenue of ₹510.22 crores. During Q1 FY26, the profit increase of the company was recorded at 23.26% YoY, and the revenue increase for the same period was 11.17%. 

Caplin Point Laboratories Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Caplin Point Laboratories Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Caplin Point Laboratories Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Caplin Point Laboratories clocked Q1 FY26 consolidated revenue of ₹510.22 crores vs ₹458.96 crores. 
• On the profit front, Caplin Point Laboratories earned a consolidated PAT of ₹152.80 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹123.97 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 23.26% YoY, and revenue rose 11.17% YoY. 
• As per the standalone figures, the quarterly PAT of Caplin Point Laboratories has increased by 18.40%, and revenue has decreased by 1.65% YoY.

Caplin Point Laboratories Share Price Performance

On the opening bell of 6th August 2025, the shares of Caplin Point Laboratories opened at ₹1,924.90 per share. However, the initial gains are sustained as of now, and Caplin Point Laboratories shares are trading at ₹1,998.10 per share, higher than their opening price. 

Considering the long-term performance, Caplin Point Laboratories shares have yielded close to 26.44% returns in the past 1 year, and 5-year returns stand at 241.39%. Over the maximum timeframe, the Caplin Point Laboratories share provided 4,952% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Caplin Point Laboratories shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Best Penny Stocks for Long Term in India | Penny Stocks in 2025

Berger Paints Q1 Results FY26: Q1 PAT Narrows 11.01% to ₹314.63 Crore; Revenue Surged 3.55% YoY

Tega Industries Q1 Results FY26: Q1 PAT Falls 3.83% to ₹35.34 Crore; Revenue Jumps 4.74% YoY

Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY

BLS International Services Q1 Results FY26: Q1 PAT Soars 49.76% to ₹171.00 Crore; Revenue Up 44.23% YoY